Method of providing celiprolol therapy to a patient

Abstract

The present disclosure relates to the field of treatment of an orphan disease, in particular treatment of vascular Ehlers-Danlos syndrome (vEDS). More specifically, the present disclosure relates to novel up-titration dosage regimens (e.g., escalating dosage regimens) effective for treating vEDS patients with celiprolol.

1 . A method for treating vascular Ehlers-Danlos syndrome,
 comprising administering to a patient in need thereof a 80 to 100 mg daily dose of celiprolol, or an equivalent amount of a pharmaceutically acceptable salt thereof, and increasing the daily dose to at least 360 mg per day of celiprolol, or an equivalent amount of a pharmaceutically acceptable salt thereof, from the end of three months.   
     
     
         2 . The method of  claim 1 , wherein at least a 80 to 100 mg daily dose increase is made within two months. 
     
     
         3 . The method of  claim 1 , wherein the daily dose is least 400 mg of celiprolol hydrochloride per day from the end of three months. 
     
     
         4 . The method of  claim 1 , wherein the daily dose is about 200 mg of celiprolol hydrochloride twice per day from the end of the three months. 
     
     
         5 .- 29 . (canceled) 
     
     
         30 . A method for treating vascular Ehlers-Danlos syndrome, comprising administering to a patient in need thereof:
 a dosage of about 91.25 mg celiprolol, or an equivalent amount of a pharmaceutically acceptable salt thereof, per day for one month,   at least a dosage of about 182.5 mg celiprolol, or an equivalent amount of a pharmaceutically acceptable salt thereof, per day for one month,   at least a dosage of about 273.75 mg celiprolol, or an equivalent amount of a pharmaceutically acceptable salt thereof, per day for one month, and   at least a dosage of about 365 mg celiprolol, or an equivalent amount of a pharmaceutically acceptable salt thereof, from the end of the third month.   
     
     
         31 . The method of  claim 30 , wherein 182.5 mg celiprolol, or an equivalent amount of a pharmaceutically acceptable salt thereof, is administered twice per day from the end of the third month. 
     
     
         32 . The method of  claim 30 , wherein at least about 400 mg celiprolol hydrochloride per day is administered from the end of the third month. 
     
     
         33 . The method of  claim 30 , wherein 200 mg celiprolol hydrochloride twice per day is administered from the end of the third month.